Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071487 | 0.91 | PTGER1 (0.38) | PTGER1CYP2C9MAPK14 | |
| SCHEMBL4079593 | 0.89 | MAPK14 (0.40) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4197723 | 0.81 | MAPK14 (0.44) | MAPK14 | |
| Hydrochloric Acid SCHEMBL4073654 | 0.79 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL4127757 | 0.78 | PTGER1 (0.46) | PTGER1CYP2C9 | |
| SCHEMBL4130612 | 0.78 | FLT1 (0.43) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4132478 | 0.78 | MAPK14 (0.43) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4075129 | 0.75 | MAPK14 (0.39) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL13946422 | 0.75 | FLT1 (0.42) | FLT1MAPK11MINK1MAPK14 | |
| Hydrochloric Acid SCHEMBL4358932 | 0.75 | MAPK14 (0.40) | FLT1MAPK11MINK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| EP-1984363-A1 | TRIAZOLOPYRIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012079-A1 | Triazolopyridine Compounds | MAPKAPK5, MAPK1, MAPK4 | PTGER1 404/4885CYP2C9 1871/4885FLT1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.